May 23rd 2025

Cardiawave takes a major step forward toward a new era in the non-invasive ultrasound therapy #NIUT of Symptomatic Severe Aortic Stenosis (sSAS) ! 🎉
 
We are proud to share the positive 100 patients – 12-month results from « Valvosoft®FIM Study » and « Valvosoft® Pivotal Study » presented on May 22 at @EuroPCR 2025 in Paris by Prof.@ Eltchaninoff.
 
They show that the treatment is safe, feasible, and efficient:
 
The results confirm the promise of non-invasive ultrasound therapy (NIUT) previously observed in earlier clinical studies:
 
✅91% MACE-free at 30 days
✅+43% increase in AVA (aortic valve area) vs natural progression of the disease
✅+9 points in KCCQ (QoL)
✅85% of patients with improved or stable NYHA class
 
These positive results pave the way for new indications, such as pre-TAVI preparation, and mark a major milestone towards the commercialization of Valvosoft®.
 
🙏 A heartfelt thank you to the clinical investigators, Cardiawave founders, investors and team for their trust and support.
 
🔗Learn more about our NIUT technology: https://cardiawave.com/cardiawave-announces-positive-12-month-results-from-its-valvosoft-fim-study-and-valvosoft-pivotal-study-presented-at-europcr/